Spec. Thanks for appreciating my opinion and posts. While...

Spec. Thanks for appreciating my opinion and posts. While pessimistic, I reject that they are blind. All are backed by research and analysis. Here I didn't do as much research so I asked for help to validate my best guess. Which you provided. And I appreciate.

The first half of 2020 was not a success in terms of sales activity. It was not a bunch of pre trials converting or DRO succeeding during a global succession. The first half of 2020 was largely one sale from 2018 that the client refused to pay for so DRO just shipped it in 2020 and recorded it as revenue making the revenue look impressive but the cash flow tell the real story. one of increasing losses. and why they needed this capital raise.

I think the market will want not price this as a success because it was not one. I at least want to see substantial and continued sales and a push above breakeven for four consecutive quarters to indicate that DRO will not just need perpetual capital raises.